Clinical trial
A Phase 2 Study of the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Epetraborole Tablets for the Treatment of Adults With Phlebotomy-Dependent Polycythemia Vera
NCT07891533 is registered in ClinicalTrials.gov with AN2 Therapeutics, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Epetraborole Tablets for the Treatment of Adults With Phlebotomy-Dependent Polycythemia Vera
- Lead sponsor
- AN2 Therapeutics, Inc
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- June 30, 2030
- Enrollment
- 75 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
polycythemia vera (snomed ct: 109992005)
Arms
As registered; 5 arms.
-
Sentinel Cohort
Open Label Fixed Dose Epetraborole
-
Part 1: Dose Selection Cohort
Open Label Epetraborole Dose Selection
-
Part 2: Epetraborole (Double Blind)
Fixed Dose Epetraborole
-
Part 2: Placebo (Double Blind Randomized Withdrawal)
Placebo Control
-
Part 3: Open Label Extension Cohort (Optional)
Open Label Epetraborole
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Part 2: Proportion of Participants per Treatment Group Maintaining Clinical Success defined as hematocrit control, not undergoing therapeutic phlebotomy and completing 12 weeks of treatment in Part 2
Lead sponsor's other trials
AN2 Therapeutics, Inc, most recent start first.
+1 more trial
Similar trials
Same condition (Polycythemia Vera) and phase, most recent start first.
+86 more trials See the condition page